Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...
Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.
At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown its team year-over-year. At a time when many life sciences companies are ...
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92, signifying a +1.51% move from its prior day's close. We recently published a list of the 11 Best Pharma Stocks to Buy ...
Vertex AI is a fully-managed, unified AI development platform for building and using generative AI. This repository is designed to help you get started with Vertex AI. Whether you're new to Vertex AI ...
AlgoTx’s mid-stage stumble on Tuesday comes after Vertex earlier this month won the FDA’s approval for Journavx, an inhibitor of the NaV1.8 voltage-gated sodium channel that marks the first new ...
Latigo Biotherapeutics, a non-opioid pain biotech looking to ride the waves created by Vertex Pharmaceuticals’ pain drug approval last month, is targeting up to … ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback